SERB LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -7.6%

  £22,565,000 → £20,854,000

• Cash

  +20.1%

  £10,357,000 → £12,441,000

• Net assets

  -4.9%

  £29,332,000 → £27,884,000

• Employees

  0%

  28 → 28

• Operating profit

  -38.6%

  £8,326,000 → £5,116,000

• Profit before tax

  -55.1%

  £7,734,000 → £3,470,000

• Wages

  -4.6%

  £2,769,000 → £2,643,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. SERB LTD 2019-01-03 → present
2. LABORATOIRES SERB UK LIMITED 2012-10-31 → 2019-01-03

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Kreston Reeves Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that may cast significant doubt on the Group's or the parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. SERB LTD · parent
   1. March Medical Limited 100% · United Kingdom · Non-trading holding company
   2. Veriton Pharma Limited 100% · United Kingdom · Development and sale of pharmaceutical products
   3. Special Products Limited 100% · England · Dormant
   4. Veriton Pharma FZ-LLC 100% · United Arab Emirates · Sales office
   5. Veriton Pharma PTY 100% · Australia · Dormant

Significant events

• “The Group was restructured to remove two dormant entities: March Medical Limited and Special Products Limited.”
• “The Company also recognised an impairment loss of £7,500,000 in respect of its investment in Veriton Pharma Limited.”
• “S Jenkinson was appointed as a director on 1 January 2025.”
• “The audit registration of Kreston Reeves LLP was transferred to Kreston Reeves Audit LLP on 6 October 2025.”
• “March Medial Limited and Special Products Limited entered into liquidation and were dissolved via voluntary strike-off on 17 March 2026.”
• “An interim dividend of 21,068 pence per Ordinary share was paid during the year.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.